NASDAQ$SLNO
Soleno Therapeutics Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Soleno Therapeutics reported financial results for Q4 2023 and provided a corporate update.
Soleno Therapeutics reported a net loss of $11.3 million for the fourth quarter of 2023. The company's research and development expenses were $8.7 million, and general and administrative expenses were $4.1 million. As of December 31, 2023, Soleno had cash and cash equivalents of approximately $169.7 million.
- Announced positive statistically significant top-line data from the randomized withdrawal period of Study C602.
- Planned NDA submission for DCCR in PWS remains on track for mid-2024.
- Closed on gross proceeds of approximately $129 million from an underwritten public offering.
- Strengthened leadership team with appointments of Meredith Manning, M.B.A as Chief Commercial Officer, Dairine Dempsey, Ph.D. as Vice President, Europe and Lauren Budesheim, M.S. as Vice President of Human Resources.
Headline financials
Revenue & EPS history
Soleno Therapeutics · Revenue · Quarterly
$3.45M
Forward guidance
Soleno remains focused on preparing an NDA submission for DCCR in PWS mid-2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2023
-1.8%
Avg return
Earnings day
-1.6%
Avg return
5 days after
-0.6%
Avg return
30 days after
38%
18 / 48 earnings
Positive
+15.2%
Q4 2014
Best reaction
-26.4%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.0% | -0.0% | — | |
| Q4 2025 | -7.1% | -8.1% | -26.7% | |
| Q3 2025 | -26.4% | -27.5% | -19.5% | |
| Q2 2025 | -3.2% | +2.7% | -14.1% | |
| Q1 2025 | +2.2% | -0.3% | +1.1% | |
| Q4 2024 | -2.5% | +10.2% | +41.3% | |
| Q3 2024 | +1.3% | +4.9% | -12.8% | |
| Q2 2024 | -3.5% | +0.2% | +3.9% | |
| Q1 2024 | -2.7% | -6.0% | -1.5% | |
| Q4 2023 | -1.0% | -2.8% | -7.9% | |
| Q3 2023 | -5.1% | -4.8% | +60.1% | |
| Q2 2023 | +4.3% | -2.1% | -22.9% | |
| Q1 2023 | -3.6% | -1.2% | +42.9% | |
| Q4 2022 | +3.0% | +16.3% | +87.6% | |
| Q3 2022 | +2.9% | +5.2% | -6.2% | |
| Q2 2022 | +12.7% | +11.0% | -16.2% | |
| Q1 2022 | -6.5% | +10.5% | +12.1% | |
| Q4 2021 | -3.7% | +4.9% | -8.2% | |
| Q3 2021 | -0.8% | -1.9% | -21.4% | |
| Q2 2021 | +3.8% | +4.7% | -0.8% | |
| Q1 2021 | -7.8% | -6.1% | -1.7% | |
| Q4 2020 | +0.0% | -47.5% | -50.2% | |
| Q3 2020 | -4.0% | +3.5% | -6.5% | |
| Q2 2020 | +6.1% | +4.5% | +20.7% | |
| Q1 2020 | -5.0% | -3.2% | -48.2% | |
| Q4 2019 | +13.0% | +1.1% | -21.1% | |
| Q3 2019 | +10.7% | +6.4% | +34.3% | |
| Q2 2019 | -0.5% | +3.1% | -4.6% | |
| Q1 2019 | -4.1% | -4.1% | +41.2% | |
| Q4 2018 | -14.9% | -10.3% | -26.5% | |
| Q3 2018 | +1.0% | -4.3% | -22.6% | |
| Q2 2018 | -4.3% | -5.1% | -20.4% | |
| Q1 2018 | +3.1% | +8.6% | +29.8% | |
| Q4 2017 | -0.7% | +1.5% | -9.0% | |
| Q3 2017 | -13.6% | -22.7% | -17.9% | |
| Q2 2017 | +8.6% | -6.2% | +28.4% | |
| Q1 2017 | +7.2% | +1.4% | -14.5% | |
| Q4 2016 | +6.3% | +0.1% | -14.7% | |
| Q3 2016 | -0.8% | +0.0% | -17.5% | |
| Q2 2016 | -5.1% | -2.4% | +8.6% | |
| Q1 2016 | -4.3% | — | — | |
| Q4 2015 | -9.1% | — | — | |
| Q3 2015 | -3.7% | — | — | |
| Q2 2014 | -14.1% | — | — | |
| Q2 2015 | -14.2% | — | — | |
| Q1 2015 | -14.3% | — | — | |
| Q4 2014 | +15.2% | — | — | |
| Q3 2014 | +0.6% | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro